GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SK Bioscience Co Ltd (XKRX:302440) » Definitions » Forward PE Ratio

SK Bioscience Co (XKRX:302440) Forward PE Ratio

: 0.00 (As of Today)
View and export this data going back to 2021. Start your Free Trial

SK Bioscience Co's Forward PE Ratio for today is 0.00.

SK Bioscience Co's PE Ratio without NRI for today is 143.95.

SK Bioscience Co's PE Ratio for today is 202.09.


SK Bioscience Co Forward PE Ratio Historical Data

The historical data trend for SK Bioscience Co's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SK Bioscience Co Annual Data
Trend 2021-12 2022-12 2023-12 2024-01
Forward PE Ratio
40.16 27.78 64.10 61.73

SK Bioscience Co Quarterly Data
2021-12 2022-03 2022-06 2022-09 2022-12 2023-03 2023-06 2023-09 2023-12
Forward PE Ratio 40.16 23.04 16.58 11.53 27.78 47.85 322.58 63.29 64.10

Competitive Comparison

For the Biotechnology subindustry, SK Bioscience Co's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SK Bioscience Co Forward PE Ratio Distribution

For the Biotechnology industry and Healthcare sector, SK Bioscience Co's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where SK Bioscience Co's Forward PE Ratio falls into.



SK Bioscience Co Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


SK Bioscience Co  (XKRX:302440) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


SK Bioscience Co Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of SK Bioscience Co's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


SK Bioscience Co (XKRX:302440) Business Description

Traded in Other Exchanges
N/A
Address
310, Pangyo-ro, Bundang-gu, Gyeonggi-do, Seongnam-si, KOR, 13494
SK Bioscience Co Ltd is a South Korean pharmaceutical company. It is engaged in the manufacturing and developing of vaccine. The company has registered SKYCellflu prefilled syringe (PFS), the first cell culture influenza vaccine in Korea, followed by the licensure of SKYCellflu Quadrivalent prefilled syringe and 13-valent Pneumococcal Conjugate Vaccine. Further it has several other vaccines under development and clinical trials including recombinant rotavirus vaccine. In addition, the development of new typhoid conjugate vaccine and innovative pneumococcal vaccine is ongoing in collaboration with external partners.

SK Bioscience Co (XKRX:302440) Headlines

No Headlines